As one of the most widely used b-blocking agents, metoprolol is also a popular drug in research studies. A number of published studies describe the pharmacokinetics as well as the pharmacodynamics of…
Simulations Plus Sets Date for Third Quarter Earnings Release and Conference Call
Conference Call to be on Tuesday, July 15, at 4:15 PM EDT
Simulations Plus Releases Major Software Update for its Top Rated Predictive Software
ADMET Predictor™ 3.0 Employs New Technology for Molecular Descriptors, All New Predictive Models
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability
The nucleoside analog R1479 is a potent and highly selective inhibitor of NS5b-directed hepatitis C virus (HCV) RNA polymerase in vitro.
Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data
Analogous to the fraction unbound in microsomes (fumic), fraction unbound in hepatocyte incubations (fuhep) is an important parameter in the prediction of intrinsic clearance and potential drug-drug interactions.
PBPK Modeling of Metoprolol and Its Metabolites
Develop a model describing absorption and pharmacokinetics of metoprolol and the formation and pharmacokinetics of its metabolites.
Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug
The objectives of the study was to develop a dissolution test method that can be used to predict the oral absorption of montelukast sodium, and to establish an in vitro/in vivo correlation (IVIVC) using computer simulations.
U.S. EPA Licenses Simulations Plus’ ADMET Predictor™ Software
Agency Licenses Both Toxicity and New Enslein Metabolism Modules
Applications of Physiologically Based Absorption Models in Drug Discovery and Development
This article describes the use of physiologically based models of intestinal drug absorption to guide the research and development of new drugs.
Simulations Plus Releases Software Update for Better Pharmaceutical Drug Design
ClassPharmer™ 4.5 Adds Powerful New Capabilities for Drug Molecule Design and Data Mining
Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man
UK-453,061 is a novel second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Following intravenous bolus administration of UK-453,061 in male rat and infusion administration in dog...
Simulations Plus Software Most Accurate in Comparison Study
Pfizer Study Presented at International Society for the Study of Xenobiotics (ISSX) Meeting in Shanghai
Simulations Plus Releases Major GastroPlus™ Software Update
Version 6.0 Incorporates Major Upgrades to Several Modules, Additional User Conveniences
Simulation of Sublingual and Gastrointestinal Absorption of Nifedipine
To develop an integrated model for drug absorption from the oral cavity. The model simulates combined absorption of a drug from both the oral cavity and the gastrointestinal tract.
Simulation of Gabapentin Absorption and Bioavailability in Pediatric Patients
To fit an absorption-pharmacokinetic model for simulation of Gabapentin in adult and pediatric populations. The model will be able to describe the nonlinear dose dependence of absorption mediated by an amino…
GlaxoSmithKline Renews and Expands Global License for Simulations Plus Software
Company Adds Parsippany, NJ Site to Multi-year Agreement
Simulations Plus Reports Second Quarter and Six Months FY2008 Financial Results
Revenues Up 4.3%, and Earnings Up 9.0% for First 6 Months of FY2008
Simulations Plus Sets Date for Second Quarter Earnings Release and Conference Call
Conference Call to Be on Tuesday, April 15, at 4:15 PM EDT
U.S. FDA Renews and Expands GastroPlus(TM) Software License
Adds New ADMET Predictor(TM) Module